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Human cytomegalovirus (HCMV) is a significant cause of
disease in immune-compromised adults and immune na-
ïve newborns. No vaccine exists to prevent HCMV infec-
tion, and current antiviral therapies have toxic side effects
that limit the duration and intensity of their use. There is
thus an urgent need for new strategies to treat HCMV
infection. Repurposing existing drugs as antivirals is an
attractive approach to limit the time and cost of new
antiviral drug development. Virus-induced changes in in-
fected cells are often driven by changes in cellular kinase
activity, which led us to hypothesize that defining the
complement of kinases (the kinome), whose abundance
or expression is altered during infection would identify
existing kinase inhibitors that could be repurposed as new
antivirals. To this end, we applied a kinase capture tech-
nique, multiplexed kinase inhibitor bead-mass spectrom-
etry (MIB-MS) kinome, to quantitatively measure pertur-
bations in >240 cellular kinases simultaneously in cells
infected with a laboratory-adapted (AD169) or clinical
(TB40E) HCMV strain. MIB-MS profiling identified time-de-
pendent increases and decreases in MIB binding of mul-
tiple kinases including cell cycle kinases, receptor tyro-
sine kinases, and mitotic kinases. Based on the kinome
data, we tested the antiviral effects of kinase inhibitors
and other compounds, several of which are in clinical use
or development. Using a novel flow cytometry-based as-
say and a fluorescent reporter virus we identified three
compounds that inhibited HCMV replication with IC50 val-
ues of <1 M, and at doses that were not toxic to unin-
fected cells. The most potent inhibitor of HCMV replica-
tion was OTSSP167 (IC50 <1.2 nM), a MELK inhibitor,
blocked HCMV early gene expression and viral DNA
accumulation, resulting in a >3 log decrease in virus
replication. These results show the utility of MIB-MS
kinome profiling for identifying existing kinase inhibitors
that can potentially be repurposed as novel antiviral
drugs. Molecular & Cellular Proteomics 16: 10.1074/
mcp.M116.065375, S263–S276, 2017.
Developing a new antiviral drug can take over a decade and
cost more than a billion dollars before approval for use in
patients (1). Even then, the majority of drugs in development
will not meet the criteria for Food and Drug Administration
(FDA) approval. This arduous development process delays
new treatments from reaching the clinic and greatly increases
healthcare costs. Repurposing of existing drugs for use as
antivirals provides an alternative to the traditional drug devel-
opment process and leverages the fact that viruses manipu-
late many of the same cellular pathways dysregulated in other
diseases states. Drugs targeting these mutual signaling
events may have unintended uses as novel antiviral therapies.
There are currently thousands of FDA-approved drugs whose
effect on virus replication has not been examined. As these
drugs have already been tested for safety and bioavailability in
humans, they could be rapidly repurposed for clinical use (2).
Thus repurposing of FDA-approved drugs as antivirals is a
rapid, cost-effective means to identify new treatments for viral
infections.
Human cytomegalovirus (HCMV)1 is a pervasive public
health issue (3). Primary infection during pregnancy is the
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leading cause of congenital birth defects, and reactivation of
latent infection during immunosuppression can lead to signif-
icant morbidity and mortality (4). The few drugs available to
treat HCMV infection are associated with severe side effects,
and no vaccines for HCMV currently exist (5). In addition, the
emergence of drug-resistant HCMV strains has become in-
creasingly common (6). Thus new antiviral drugs are greatly
needed to curtail HCMV disease.
The extensive manipulation of cellular signaling pathways
by HCMV suggests that drug repurposing may be an espe-
cially useful approach to identify new antiviral drugs. HCMV
has a prolonged replication cycle that is tightly integrated into
the state of the infected cell. Thus, HCMV actively manipu-
lates a multitude of cellular signaling pathways to facilitate
virus replication, including inhibition of cellular intrinsic de-
fenses and activation of pathways that control protein syn-
thesis and metabolism (7–14). These changes generate a
cellular environment conducive for virus replication and serve
as potential targets to limit HCMV disease. Recent studies
have taken advantage of high throughput screening opportu-
nities to search for protein kinase inhibitors (15, 16) or other
compounds that may block HCMV replication (17).
Manipulation of host kinase activity accounts for many of
the changes in cellular signaling observed during HCMV in-
fection. HCMV inhibits several cellular kinases critical for the
innate immune response such as protein kinase R, which
potently suppresses HCMV replication when activated (13).
The HCMV TRS1 and IRS1 proteins antagonize protein kinase
R activation, ensuring continued synthesis of viral proteins
and limited expression of interferon-dependent genes (18).
Conversely, infection also activates cellular kinases that drive
signaling pathways that promote virus replication. Specifi-
cally, HCMV activates the AMPK and mTOR kinases to in-
crease glycolysis and fatty acid synthesis to generate ana-
bolic metabolites required for the production of infectious
virus (19–22). Inhibiting AMPK or mTOR activity dramatically
decreases virus replication (21, 23). Thus, the coordinated
activation and inhibition of cellular kinases is a critical aspect
of HCMV replication.
Dysregulated kinase activity underlies multiple disease
states such as cancer, autoimmunity and diabetes. As a re-
sult, kinase inhibitors are a promising class of drugs for treat-
ment of a wide range of diseases, and could potentially be
repurposed for use as HCMV antivirals (24, 25). For instance,
multiple cancer cell types show increased mTOR activity and
an ATP-competitive mTOR kinase inhibitor Torin1 was devel-
oped as an effective cancer treatment. Based on the increase
in mTOR activity during HCMV infection, we previously found
that a specific mTOR inhibitor, Torin1, inhibited lytic replica-
tion of representative alpha-, beta-, and gammaherpesvirus
(23). Further, transplant recipients treated with the mTOR
inhibitor rapamycin showed decreased incidence and severity
of HCMV disease (26). These examples highlight the clinical
utility of repurposing existing kinase inhibitors targeting
HCMV-induced kinases as novel antiviral therapeutics.
Although the above examples demonstrate the importance
of a small subset of cellular kinases in HCMV replication, the
full complement of virus-induced changes to the host kinome
are unknown. The sheer number of human kinases (500)
presents a significant hurdle to measuring each kinase during
infection using standard approaches, particularly those where
antibodies or other reagents are unavailable. Kinome profiling
was developed to facilitate the quantitative measurement of
changes in hundreds of kinases from a single sample (27).
Multiplexed kinase inhibitor beads coupled with mass spec-
trometry (MIB-MS), is an adaption of the original KinoBead
method described by Daub, Kuster and others (28–33). Using
immobilized pan kinase inhibitors for kinase capture, MIB-MS
can be used to quantify differences in kinase expression/
abundance and in some instances, kinase activity between
samples (34–36). Similar examples of immobilized kinase in-
hibitor capture have proven the utility of this methodology to
study the kinome (For review see (29)). Coupled with quanti-
tative mass spectrometry (MS), the difference in the amount of
captured kinase from each sample provides a global and
unbiased view of kinome perturbations between samples.
Additionally, methods such as KinActiv (25), and targeted
MRM-based approaches (38) can be applied to profile
changes in the activation state of the kinome.
Our research group and others have applied MIB-MS ki-
nome profiling to define kinome adaptations to select kinase
inhibitors, to acquired drug resistance and to epigenetic in-
hibitors (27, 35, 39, 40). MIB-MS proteomics has also been
used to characterize the kinome of model organisms (41). In
infectious disease, kinome profiling provided an in-depth pic-
ture of how Ebola virus infection altered liver cell signaling
networks, and identified new host targets for novel antiviral
drugs (42, 43). These examples demonstrate the utility of
kinome profiling for identifying changes in kinase activity as-
sociated with multiple disease states.
The objective of this study was to use MIB-MS kinome
profiling to identify temporal alterations in the host kinome
induced by HCMV infection. Our ultimate goal was to eluci-
date virus-induced changes to the host kinome that could be
targeted with existing kinase inhibitors to limit HCMV replica-
tion. Using two different HCMV strains, we compared the
abundance/activity of 240 kinases in uninfected and in-
fected cells over a time course of infection. Both lab-adapted
AD169 strain and the TB40/E clinical strain induced remark-
ably consistent kinome changes, which were predicted to
affect multiple signaling pathways and a wide variety of cel-
lular processes. Our MIB-MS results directed our efforts to
test a number of kinase inhibitors for their antiviral effects.
Using a simple assay to quantify the effects of these inhibitors
on HCMV replication, we identified three kinase inhibitors
currently in clinical development or use that significantly de-
creased HCMV replication. One such compound, OTSSP167,
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potently inhibited HCMV replication at nanomolar concentra-
tions not toxic to uninfected cells. These data demonstrate
the utility of MIB-MS kinome profiling for defining novel virus-
induced kinome changes and for identifying host pathways
that can be targeted by existing or emerging drugs to limit
virus replication.
MATERIALS AND METHODS
Cells and Viruses—Primary human MRC-5 fibroblasts were ob-
tained from the ATCC and cultured in DMEM containing 10% fetal
bovine serum and penicillin/streptomycin. In all experiments, cells
were used between passage 7 and 21. The HCMV AD169inGFP
strain, which contains a GFP expression cassette inserted in the
UL21.5 locus (44), was used as the wild type HCMV strain. The
pp28-GFP virus has been described previously (45). This virus ex-
presses the HCMV pp28 protein as a GFP fusion protein from its
native location in the HCMV genome under the control of its endog-
enous promoter, and replicates with similar kinetics and efficiency as
wild type HCMV. Unless otherwise noted. Infections were performed
at a multiplicity of infection (MOI) of one. Cell free HCMV was quan-
tified using the TCID50 method on primary human fibroblasts as
previously described (46).
For TGF treatment, MRC-5 fibroblasts were serum-starved for
24 h. Cells were infected with HCMV AD169inGFP at an MOI of 3.
Forty-eight hours after infection cells were treated with 4 g of human
TGF-1 (Cell Signaling Technology, Danver, MA; #5154) for 4 h prior
to harvest.
MIB-MS Kinome Profiling—Cell pellets were lysed in MIB-MS lysis
buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 0.5% Triton X-100, 1 mM
EDTA, 1 mM EGTA, 10 mM NaF, 2.5 mM NaV04 plus Protease Inhibitor
Mixture (Roche, Basel, Switzerland) and Phosphatase Inhibitor Mix-
ture 2 (Sigma, St. Louis, MO; # P5726) and 3 (Sigma P0044). Samples
were sonicated and clarified by centrifugation at 14,000  g and
supernatants filtered through a 0.2 m filter (Corning, Roche, Basel,
Switzerland; # 431219). Protein amounts were quantified by Bradford
protein assay and the concentration of protein was normalized across
samples prior to adjusting salt concentration to 1 M NaCl. MIB-MS
columns composed of 4 immobilized kinase inhibitors (PP58, Purv-
alanol B, VI16832, and UNC21474), were prepared by mixing equal
proportions of immobilized kinase inhibitors in a final volume of 200 l
settled beads. Columns were equilibrated with MIB-MS high salt
buffer (50 mM HEPES, pH 7.5, 1 M NaCl, 0.5% Triton X-100, 1 mM
EDTA, and 1 mM EGTA) prior to passing samples over MIBs columns
by gravity flow. MIB columns were sequentially washed with MIB-MS
high salt buffer, MIB-MS low salt buffer (50 mM HEPES, pH 7.5, 150
mM NaCl, 0.5% Triton X-100, 1 mM EDTA, and 1 mM EGTA), and SDS
wash buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 0.5% Triton X-100,
0.1% SDS, 1 mM EDTA, and 1 mM EGTA). Proteins were eluted from
MIB columns by boiling for 15 min in elution buffer (100 mM Tris-HCl,
pH 6.8, 0.5% SDS, 1% -mercaptoethanol) twice. DL-DTT was added
to a final concentration of 5 mM and samples were incubated at 60 °C
for 25 min. Samples were cooled to room temperature on ice and
iodoacetamide was added to a final concentration of 20 mM. Samples
were incubated for 30 min at room temperature in the dark. DL-DTT
was added to bring the final concentration to 10 mM and sam-
ples were incubated at room temperature for 5 mins in the dark.
Samples were then concentrated to a final volume of 100 l in 10K
Amicon Ultra centrifugal concentrators and proteins purified by meth-
anol chloroform extraction. Samples were re-suspended in 50 mM
HEPES, pH 8.0, and digested with sequencing grade porcine trypsin
(Promega, Madison, WI) overnight at 37 °C. Samples were extracted
with ethyl acetate 3 times to remove residual detergent and desalted
using Pierce C-18 spin columns according to the manufacturer’s
protocol.
LC/MS/MS Analysis—The peptide samples were analyzed by LC/
MS/MS using an Easy nLC 1000 coupled to a QExactive HF mass
spectrometer (Thermo Scientific, Waltham, MA). Samples were in-
jected onto an Easy Spray PepMap C18 column (75 m id  25 cm,
2 m particle size) (Thermo Scientific) and separated over a 2 h
method. The gradient for separation consisted of 5–32% mobile
phase B at a 250 nl/min flow rate, where mobile phase A was 0.1%
formic acid in water and mobile phase B consisted of 0.1% formic
acid in ACN. The QExactive HF was operated in data-dependent
mode where the 15 most intense precursors were selected for sub-
sequent fragmentation. Resolution for the precursor scan (m/z 400–
1600) was set to 120,000 with a target value of 3  106 ions. MS/MS
scans resolution was set to 15,000 with a target value of 2 104 ions.
The normalized collision energy was set to 27% for HCD. Peptide
match was set to preferred, and precursors with unknown charge or
a charge state of 1 and  8 were excluded.
Data Analysis—Raw data files were processed using MaxQuant
version 1.5.3.17 and searched against the reviewed Uniprot human
database (containing 20,203 entries, downloaded Aug 2015), ap-
pended with a Uniprot HCMV AD169 or TB40/E database and con-
taminants database, using Andromeda within MaxQuant. Enzyme
specificity was set to trypsin, up to two missed cleavage sites were
allowed, carbamidomethylation of C was set as a fixed modification
and deamidation of N, Q, oxidation of M, phospho of S, T, Y, and
acetyl of N terminus were set as variable modifications. The mass
tolerance for precursor (main search) and product ions was set to 6
ppm and 20 ppm, respectively. A 1% FDR was used to filter all data.
Match between runs was enabled, and a minimum of two unique
peptides was required for label-free quantitation (LFQ) using the LFQ
intensities. Data are available via ProteomeXchange (www.proteomex-
change.org, project ID PXD005276) with identifier PXD005276.
Experimental Design and Statistical Rationale—Two biological rep-
licates for each time point after infection with HCMV AD169 and two
biological replicates for each time point after HCMV TB40/E infection
(0, 24, 48, 72 h) were used for MIB-MS experiments, in sum providing
four independent replicates for each time point. Assessment of indi-
vidual MaxQuant analyses conducted for both strain and replicate
showed consistent results between strains and replicates; therefore,
the data sets from both strains and replicates were merged to provide
a more robust analysis. We selected a set of 25 proteins in an
unbiased manner by ranking them in terms of their variability across
all samples from largest to smallest based upon median absolute
deviation, a robust measure of variability. We then performed hierar-
chical clustering of the log transformed protein intensities from each
of these 25 most variable proteins using 1 - the Spearman’s correla-
tion as the distance metric. The clustering profile indicates that sam-
ples cluster strongly together by time point rather than virus type,
indicating similar temporal patterns of change.
Statistical testing based upon these samples was performed to
identify those kinases whose patterns showed strong temporal
changes in expression that were consistent across all replicates.
Statistical analyses were performed in the R statistical programming
language version 3.3.1. Biological duplicates from each strain were
searched separately in MaxQuant, and LFQ values from all four
MaxQuant runs were merged into a single data set consisting of n 
16 samples (four time points per run). To reduce our data set to a
subset of consistently observed kinases, we removed those kinases
that were found to have less than or equal to two peptides in all four
MaxQuant runs, in addition to kinases that had greater than 35%
missing values (LFQ value of 0) across samples in the merged data
set.
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To determine which kinases showed consistent temporal trends in
expression, we utilized linear mixed models (47,48) to model the log
LFQ for each particular kinase with respect to time, accounting for
correlation between samples within each run as well potential inter-
run heterogeneity in kinase trends. Specifically, we utilized a linear
mixed model with a run-level random intercept and a run-level ran-
dom slope with respect to time, treating time as a continuous variable.
Similar to previous studies, Log LFQ values were assumed to be
approximately normally distributed (49). Mock samples were treated
as a zero hour time point. p values for the significance of the esti-
mated time trend coefficient were computed using the summary
function from the lmerTest (50) package on the fitted model, testing
the null hypothesis that the slope of the time trend is equal to zero. p
values from each kinase were corrected for multiple testing using
the Benjamini-Hochberg procedure (51) kinases with adjusted p val-
ues less than 0.05 were considered to have a significant trend in ex-
pression over time. Hierarchical clustering was utilized to display
changes in observed log LFQ intensity with respect to the set of
kinases showing such significant time trend (1 - Spearman Corre-
lation distance metric). Pairwise changes between a single time
point and the mock sample were similarly computed using linear
mixed models, testing the null hypothesis that the difference in log
LFQ between a given time point and the mock sample is 0, where
within-run correlation is accounted for with a run-level random
intercept. Raw and adjusted p values were reported for each ki-
nase, as well as model estimates for time (log LFQ scale) for the
trend analysis or difference in log LFQ for the pairwise analyses.
Prior to statistical analysis, missing kinases were imputed by first
calculating the covariance matrix between samples using only pair-
wise complete observations. Then, for each kinase with missing
values, a single sample was randomly drawn from a multivariate
normal distribution with the calculated covariance matrix and mean
predicted from the trend between time and the non-missing LFQ
values for that kinase (linear mixed model). Missing values in the
given kinase were replaced with the corresponding elements from
this random sample.
Analysis of Protein Expression—Analysis of proteins levels by
Western blot was performed essentially as described previously (52).
Briefly, infected cells were pelleted and stored at 80 °C until use.
Cell lysates were prepared by resuspending cell pellets in RIPA buffer
(50 mM Tris-HCl pH 7.4, 1% Nonidet P-40, 0.25% sodium deoxy-
cholate, 150 mM NaCl, 1 mM EDTA, and complete protease inhibitor
(Roche)) and incubation on ice for 15 min. Cellular debris was re-
moved by centrifugation at 21,000  g for 10 min. Total protein
concentration was determined by Bradford assay. Equal amounts of
protein were separated on SDS-PAGE gels and transferred to nitro-
cellulose or PVDF membranes. Membranes were blocked in Tris-
buffered saline containing 0.1% Tween (TBS-T) and 5% nonfat milk or
5% bovine serum albumin (BSA) for phosphoblots for 1 h at room
temperature. Blots were then incubated overnight with the indicated
antibodies. Rabbit polyclonal antibodies were diluted in TBS-T con-
taining 5% BSA and incubated with membranes at 4 °C overnight.
Mouse monoclonal antibodies were diluted in TBS-T containing 1%
BSA and incubated with membranes for at least one hour at room
temperature. After washing with TBS-T, membranes were incubated
with HRP-conjugated anti-rabbit or anti-mouse secondary antibodies
and visualized by enhanced chemiluminesence (ECL) using the Bio-
Rad (Hercules, CA) ChemiDoc system. The following commercial
antibodies were used in this study: MELK (#2274, Cell Signaling
Technologies); eIF4B (#3592, Cell Signaling Technologies) phospho-
eIF4B Ser406; (#5399, Cell Signaling Technologies); -actin (sc-
47778, Santa Cruz Biotechnology); ICP36 (UL44; 10D8, Virusys,
Taneytown, MD), tubulin (DM1A, Sigma), TGFBR2 (#A304–414A,
Bethyl, Laboratories, Montgomery, TX), Ephrin A2 (#6997, Cell Sig-
naling Technology), Ephrin B4 (#14960, Cell Signaling Technology),
phosphorylated Smad 2/3 (#8828, Cell Signaling Technology), total
Smad 2/3 (#3122, Cell Signaling Technology), IE1 (84), TRS1 (60) and
pp28 (65) were kindly provided by Dr. Tom Shenk (Princeton
University).
Quantification of Viral DNA—Viral DNA was quantified by real time
PCR (qPCR) previously described (56). Briefly, MRC5 fibroblasts were
infected with HCMV at an MOI of 0.05 and harvested by scraping. The
cell pellet was resuspended in lysis buffer (400 nM NaCl, 10 mM
Tris-HCl pH 8.0 and 10 mM EDTA). Proteinase K (40 g/ml) and SDS
(final concentration 0.16%) was then added and the cells were incu-
bated at 37 °C overnight. The lysates were extracted with phenol
followed by incubation with 40 g/ml RNase A at 37 °C for 1 h. The
lysate was again extracted with phenol followed by a chloroform
extraction. The DNA was precipitated with ethanol and resuspended
in 10 mM Tris-HCl, pH 8.0. Quantitative PCR was performed using
primers specific for the HCMV UL99 gene (UL99F 5-GTGTCCCAT-
TCCCGACTCG-3, UL99R 5-TTCACAACGTCCACCCACC-3) and
GAPDH (GAPDHF 5-CTGTTGCTGTAGCCAAATTCGT, GAPDHR 5-
ACCCACTCCTCCACCTTTGAC-3). Viral DNA abundance was deter-
mined using the absolute abundance method by comparison to a
standard curve of AD169 BAC DNA ranging from 101 to 109 copies.
GAPDH copy number was quantified using the same approach with a
standard curve consisting of the same dilution series of the GAPDH
amplicon. Viral DNA abundance in each sample was normalized to the
abundance of GAPDH to control for variation in loading.
Quantification of mRNA—Viral or cellular mRNA levels were quan-
tified by reverse transcriptase real time PCR (qRT-PCR) as described
before (57). Briefly, cell pellets were resuspended in 1 ml of Trizol
(Thermo Fisher Scientific). Total RNA was purified according to the
manufacturer’s specifications (with the exception of a 1 h incuba-
tion of isopropanol at 20 °C). Contaminating DNA was removed
using the Turbo DNase kit according to the manufacturer directions
(Thermo Fisher Scientific). One microgram of DNase-treated RNA was
reverse transcribed using High-Capacity cDNA Reverse Transcription
Kit (Thermo Fisher Scientific). Quantitative reverse transcriptase real
time PCR (qRT-PCR) was performed using SYBR green master mix
(Thermo Fisher Scientific) and the following primers: IE1F 5-CAA-
GTGACCGAGGATTGCAA-3, IE1R 5-CACCATGTCCACTCGAAC-
CTT-3; UL44F 5-GCGTGCAAGTCTCGACTAAGGAGC-3, UL44R
5-AAGTACTGTGCCTCTTAGTCGGGGG-3; UL99F 5-GTGTCC-
CATTCCCGACTCG-3, UL99R 5-TTCACAACGTCCACCCACC-3;
HO1F 5-CGTGCAGAGAATTCTGAGTTC-3, HO1R 5-AGACGCTTT-
ACGTAGTGCTG-3). The abundance of each transcript was deter-
mined using the absolute abundance method and a standard curve
consisting of 10-fold serial dilutions of the specific amplicon cloned
into the pCRBlunt vector (Invitrogen, Carlsbad, CA). Serial dilutions
from 108 to 101 were used for each gene, and the R2 value of each
standard curve was 0.98. The relative increase in HO1 mRNA levels
after TGF treatment was determined using the Ct method, with
uninfected, untreated cells serving as the reference sample.
Antiviral Drug Screen—MRC-5 fibroblasts were seeded into 96-
well plates. At confluency, the media was replaced with serum-free
DMEM for 24h. Cells were infected with HCMV-pp28GFP at an MOI
of 1 for one hour, and drugs diluted in serum-free media were added
to the cells at the time the inoculum was removed. Compounds were
purchased from Selleckchem (Munich, DE), and included: Alisertib
(S1133), PF 03814735 (S2725), LY2603618 (S2626), OTSSP167
(S7159), SBI-0206965 (S7885), TG003 (S7320), Tivatinib (S2753),
MRT67307 (S7948), Saracatinib (S1006), Sotrastaurin (S2791),
BMS-777607 (S1561), OTX015 (S7360), Dinaciclib (S2768). At 96 h
after infection the cells were washed with PBS, trypsinized, and
transferred to a round bottom plate. Cells were fixed in 4% paraform-
aldehyde for 10 min at room temperature, washed twice with PBS,
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and then resuspended in 200 l of FACS buffer. A Guava EasyCyte
HT flow cytometer (EMD Millipore) was used to determine the number
of GFP positive cells. The GFP-positive gate was set so that less than
1% of uninfected cells crossed the threshold. Drug treated wells were
normalized to vehicle treated wells for each appropriate dilution. IC50
values were calculated using GraphPad Prism software.
Cellular Toxicity Assay—Lactate dehydrogenase release was used
to assess drug toxicity to uninfected cells as per the manufacturer’s
directions (Sigma). For the initial screen of kinase inhibitors, MRC-5
cells were serum starved overnight before addition of the drugs.
Ninety-six hours after addition of the drugs, LDH activity in the su-
pernatant was measured by absorbance at 450 nm and normalized to
the activity in untreated media.
RESULTS
MIB-MS Kinome Profiling Identifies Host Signaling Path-
ways Altered by HCMV Infection—We utilized MIB/MS profil-
ing to identify time-dependent changes in the human kinome
throughout HCMV infection using the laboratory strain,
AD169, and the clinical strain TB40/E (58). Our MIB-MS col-
umns were composed of a four inhibitor (PP58, Purvalanol B,
VI16832, and UNC21474) bead mix that was optimized for
kinome capture as previously reported (27) (East, unpublished
observations). A schematic of the kinome profiling workflow is
shown in Fig. 1. Primary human fibroblasts were serum-
starved prior to infection to decrease basal signaling and
allow for better quantification of virus-induced changes in the
kinome. Infected cell lysates were harvested at 24, 48, or 72 h
after infection, and kinases were enriched from cell lysates
with MIB columns as described above. The captured kinases
were digested and identified by LC-MS/MS and the expres-
sion/abundance of each kinase relative to the uninfected con-
trol at each time point after infection was determined using
label-free quantification (MaxQuant-see Methods).
In addition to identifying changes in the kinome in response
to HCMV infection, this approach allowed us to directly com-
pare HCMV strains associated with clinical infections to their
lab-adapted counterparts. Infection with either HCMV strain
significantly altered the abundance/activity of multiple cellular
kinases as identified by MIB-MS, and these changes were
observed to be highly consistent between both strains. These
strains were first analyzed individually, and the data sets from
both strains combined to provide a more robust analysis. The
full list kinases quantified during infection is shown in supple-
mental Tables S1 and S2. Two hundred forty-four kinases
were present in all samples, and only these kinases were
included in the subsequent analyses. To generate a high
confidence list of kinases whose recovery with MIB-MS was
changed by infection, we used linear mixed models (See
Statistical Analysis in Methods) to identify kinases consis-
tently altered at multiple times after infection. The graphs
showing the linear mixed model analysis for each quantified
kinase are shown in supplemental Fig. S1. Using this conserv-
ative analysis, we found 53 kinases that were more abun-
dantly recovered after MIB-MS from infected lysates at all
times after infection (Fig. 2A). Significant among these in-
cluded the cyclin-dependent kinases (CDK 1, 7, 9, 10), recep-
tor and non-receptor tyrosine kinases (INS, MET, MERTK,
HCK, LYN), and lipid kinases (PIP4K2C, PIP4K2B, PIK3C3,
PI4K2B, PIK3R4). We also identified 51 kinases that were
consistently recovered at reduced levels from infected cell
lysates (Fig. 2A, supplemental Table S3). This group included
PDGFR (A/B), FGF (1/2), TGF- (1/2), and other receptor
tyrosine kinases (e.g. Ephrin RTKs).
The graphs showing the fold change for each kinase during
infection compared with uninfected cells are shown in sup-
plemental Figs. S2 and S3. Some kinases were consistently
altered at all times after infection (supplemental Table S3),
whereas others were significantly changed only at discreet
times after infection (supplemental Tables S4). Several of
FIG. 1. Cartoon showing workflow of kinome profiling of HCMV
infected cells. Primary human fibroblasts were infected with HCMV
at a multiplicity of 3, or left uninfected for 24, 48, or 72 h. Lysates were
passed over multiplexed inhibitor beads to enrich for kinases. The
recovered kinases were digested with trypsin, and the tryptic pep-
tides were analyzed by LC/MS/MS. Label-free quantification was
used to determine the abundance of each recovered kinase. Kinome
dynamics resulting from HCMV were determined by comparing the
abundance of each kinase in infected samples relative to uninfected
control. *Kinome tree illustration reproduced courtesy of Cell Signal-
ing Technology, Inc. (www.cellsignal.com).
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these kinase changes, such as increased AMPK and p70 S6
kinase (p70S6K), have been previously observed during
HCMV infection (21, 22). At 24 h after infection, 64 kinases
were significantly altered compared with uninfected cells (Fig.
2B). The percentage of kinases changed during infection at
each time point is shown in Fig. 2C. Overall, more kinases
were affected at 48 and 72 h, with 138 and 139 kinases
showing quantitative differences in capture by MIB-MS, re-
spectively. Together these data show that HCMV infection
significantly changes the abundance/activity of multiple cel-
lular kinases in a temporal manner.
To identify signaling pathways altered by HCMV infection,
we performed bioinformatics analysis to identify signaling net-
works significantly altered in our kinome data. We found that
infection increased or decreased signaling through multiple
biological pathways and processes. Kinases that were de-
tected in greater abundance by MIB-MS after infection were
associated with multiple signaling pathways, including the
AMPK, mTOR and ERK/MAPK signaling networks (supple-
mental Table S5). This data was consistent with previous
studies showing that HCMV infection induces the AMPK,
mTOR, and ERK kinases. Similarly, multiple pathways were
negatively impacted by infection (supplemental Table S6),
such as the NFkB and PDGFR pathways, in line with the
previously reported inhibition of NFkB and PDGFR signaling
pathways by HCMV. Thus MIB-MS kinome profiling accu-
rately identified known HCMV-induced changes in cellular
signaling pathways important for HCMV replication.
Novel Cellular Pathways Affected by HCMV Infection—Our
kinome profiling data identified multiple signaling pathways
affected by HCMV infection. For instance, the ephrin (Eph)
receptor kinases are a large family of tyrosine kinases that
play important roles in cell-to-cell communication, gene ex-
pression, and cell growth (59). HCMV infection significantly
decreased the amount of EphA4, EphB2, EphB3, and EphB4
quantified by MIB-MS at 24 h after infection (Fig. 3A). In
contrast, we found that EphA2 was slightly elevated at 24 h
after infection and slowly decreased at 48 and 72 h. To
determine if the changes in Eph receptor capture by MIBs
were because of changes in Eph kinase activity or Eph recep-
tor abundance, we measured the expression of EphA2 and
EphB4 by Western blot analysis. Infected cells expressed less
EphB4 protein (Fig. 3B) compared with uninfected controls,
whereas EphA2 levels initially increased, before declining to
levels seen in uninfected cells by 72 h after infection. The
change in EphA2 and EphB4 protein levels detected by West-
ern blots after infection closely matched the changes in
EphA2 and EphB4 quantified by MIB-MS kinome profiling.
FIG. 2. Host kinome changes quantified over a time course of HCMV infection. A, Heat map showing the quantified kinases significantly
altered during HCMV infection. Fibroblasts were infected with AD169 or TB40E at a multiplicity of one, and cellular kinases were identified and
quantified by MIB-MS kinome profiling. The heat map shows the change in kinase quantification for kinases significantly altered at multiple
times after infection. B, Graph showing the number of cellular kinases significantly changed at each time after HCMV infection as quantified
by MIBS-MS as compared with the uninfected sample. C, Percentage of kinases (of 244 total) at each time point with a significant increase,
decrease, or no change in recovery with MIB-MS after HCMV infection.
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Interestingly, the decrease in EphB4 protein abundance was
not reflected in EphB4 transcript abundance (Fig. 3C), sug-
gesting that post-transcriptional regulatory events limit EphB4
abundance in HCMV infected cells.
Interestingly, we observed a decrease in the amount of
TGF receptor subunits TGFRI and TGFRII quantified by
MIB-MS from infected cell lysates (Fig. 3D). Binding of TGF
to the TGF receptor results in phosphorylation of SMAD
family transcription factors (60). To determine if HCMV infec-
tion inhibited TGF receptor signaling, we measured SMAD
phosphorylation in response to TGF treatment in mock and
HCMV infected cells (Fig. 3E). As expected, TGF treatment
induced SMAD phosphorylation in uninfected cells. However,
no SMAD phosphorylation was observed in response to TGF
treatment of HCMV infected cells, despite the maintained or
slightly elevated levels of TGFR2. In addition we found that
HCMV infection prevented the TGF-dependent increase in
the HO1 mRNA observed in uninfected cells (Fig. 3F). Taken
together, these results suggest that HCMV infection inhibits
TGF signaling.
We also observed an increase in the serine/threonine kinase
MELK after infection. MELK is an AMPK family member in-
volved in the regulation of replication stress and cell prolifer-
ative responses (61, 62). MELK activity increases in propor-
tion to MELK expression (52), and MELK has been reported to
phosphorylate multiple proteins involved in cell cycle, tran-
scriptional and translational regulation (63–65). MIB-MS anal-
ysis identified increased MELK at 24–48 h, which decreased
FIG. 3. HCMV infection alters multiple novel signaling pathways. A, Fold change in the amount of ephrin (Eph) kinases recovered with
MIBs over a time course of HCMV infection relative to uninfected cells. Primary human fibroblasts were infected with either AD169 or TB40E
as in Fig. 1. The results are the average from all infections combined. B, MRC-5s were serum-starved for 24 h before infection with AD169 at
a multiplicity of three. The levels of the Ephrin A2 (EPHA2), Ephrin B4 (EPHB4), and IE1 proteins were measured by Western blot over a time
course of infection. The levels of tubulin were measured as a loading control. C, As in (B), levels of EphB4 mRNA levels were measured by
qRT-PCR. D, Same as in (A). E, MRC-5s were infected with AD169 at a MOI of 3 for 48 h. Cells were then treated with 4 g of TGF-1 for 4 h.
Levels of Smad2/3-P, Smad2, TGF- receptor II, and pTRS1 were determined by Western blot. F, MRC-5s were infected as in (D). Cells were
then treated with 4 g of TGF-1 for 24 h. Levels of HO1 mRNA (a Smad2/3-responsive transcript) were measured by qRT-PCR. G, Fold
change in MELK kinase as in A. H, H, Western blot for MELK expression, eIF4B Ser406, total eIF4B and actin expression as in B. I, Western
blot results for phosphorylation of the MELK substrate eIF4B (Ser406) and total eIF4B.
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after 72 h of infection (Fig. 3G). To confirm the changes in
MELK expression, we performed Western blots on lysates
after infection (Fig. 3H). As determined by Western blotting,
MELK protein levels followed the MIB-MS pattern, with the
highest levels observed at 24–48 h compared with uninfected
cells. Recently MELK was shown to phosphorylate eIF4B on
Ser406 (64). Using a phosphospecific antibody to this site
(Ser406), we found increased eIF4B Ser406 phosphor-
ylation after infection that mirrored the changes in MELK and
eIF4B protein expression (Fig. 3H). These data identify two
previously unreported effects of HCMV infection on host sig-
naling pathways, demonstrating the utility of MIB-MS kinome
profiling for identifying cellular signaling pathways altered by
HCMV infection.
Development of a Novel Assay to test HCMV Antiviral Effi-
cacy—Based on our MIB-MS kinome profile data, we identi-
fied several drugs currently in clinical use or development that
could be used to target HCMV-induced kinases. We therefore
developed a rapid assay to assess the ability of these drugs
as inhibitors of HCMV replication (Fig. 4A). Our assay uti-
lizes a recombinant virus (pp28-GFP) expressing the HCMV
pp28 protein fused to the green fluorescent protein (GFP) on
its carboxyl terminus (45). The pp28-GFP fusion protein is
expressed from its native location in the HCMV genome
under the control of its endogenous promoter. Although
pp28 expression is essential for HCMV replication, we pre-
viously showed that the pp28-GFP virus replicates with
similar kinetics and to equivalent levels as wild type HCMV (45).
As pp28 transcription requires prior viral DNA replication, inhib-
iting the HCMV lytic cycle at any step prior to viral DNA repli-
cation (e.g. entry, uncoating, immediate early and early gene
expression, etc.), will result in decreased pp28-GFP expression.
To test the applicability of this assay, we examined the
effect of a known inhibitor of HCMV DNA replication, phos-
phonoacetic acid (PAA) (66, 67), on pp28-GFP expression.
Primary human fibroblasts were infected with the pp28-GFP
FIG. 4. Analysis of potential HCMV antivirals. A, Schematic of method. Fibroblasts were treated with infected with pp28-GFP at an MOI
of 1 in a 96-well plate format. Cells were treated with seven concentrations of each drug ranging from 10 M to 2.4 nM at the time of infection.
Cells were harvested at 96 h after infection, and the GFP fluorescence of each well was determined using a Guava HTS flow cytometer. The
change in GFP fluorescence at each dose of drug was used to calculate the 50% inhibitory concentration (IC50). B, Fibroblasts were infected
as in A, and treated with a range of concentrations of PAA, a well-characterized inhibitor of viral DNA replication. The IC50 was determined
as in A. The observed IC50 value and previously reported IC50 are shown. C, Graph showing the IC50 data for drugs that significantly inhibited
pp28-GFP fluorescence. D, The dose of each drug that resulted in 50% cell death (LD50) was determined using the LDH release assay. Toxicity
data is shown for drugs that inhibit pp28-GFP fluorescence. TG003 is included in graphs C and D as an example of a drug with no effect on
pp28-GFP fluorescence or cell viability. The graphs show the mean and standard deviation of at least two experiments.
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virus and treated with a range of concentrations of PAA at
the time of infection. At 96 h after infection, pp28-GFP
fluorescence was measured using a 96-well flow cytometer.
The percent inhibition of pp28-GFP fluorescence at each
concentration was used to calculate the 50% inhibitory
concentration (IC50). PAA decreased the fluorescence of
pp28-GFP infected cells, and the observed IC50 value of
26.8 g/ml closely matched the previously reported IC50
of 20 g/ml (Fig. 4B and (66)). These data confirm that the
pp28-GFP expression assay closely recapitulates inhibition
of HCMV replication as determined by traditional molecular
techniques.
Inhibitors of Kinases Identified by MIB-MS Have Antiviral
Activity—We next used the pp28-GFP assay to measure the
potential antiviral activity of specific kinase inhibitors. The
inhibitors were selected based on three criteria. First, we
selected kinases increased in at least one time point after
HCMV infection, as detected by MIB-MS. From this list, we
chose kinase inhibitors that had been tested in humans or
were currently in clinical trials. A few additional kinase inhib-
itors were selected based on preclinical data suggesting their
potential entry into clinical trials. The list of the 13 kinase
inhibitors tested are shown in Table I. These compounds were
examined in the pp28-GFP assay for their ability to inhibit
HCMV replication.
Nine of these inhibitors had little or no effect on pp28-GFP
expression, suggesting that their kinase targets are not critical
for virus replication. However, four compounds significantly
decreased pp28-GFP expression (Fig. 4C). The bromodomain
and extraterminal (BET) proteins BRD2, BRD3, and BRD4 are
known to bind kinase inhibitors (68) and were detected by
MIB-MS after HCMV infection. Although not a kinase inhibitor,
OTX015 binds and inhibits the BRD2, BRD3, and BRD4 pro-
teins (69–71). Consistent with a role for BRD2 in HCMV rep-
lication, OTX015 inhibited HCMV replication with an IC50 of
8.5 M, although some toxicity was observed in uninfected
cells.
The Chk1 kinase plays a central role in the DNA damage
response, which is induced by HCMV infection and required
for efficient virus replication (72). Incubation with the Chk1
inhibitor LY2603618 inhibited HCMV replication with an IC50
of10 M. Dinaciclib, a CDK1,2,5,9 inhibitor in clinical testing
for the treatment of solid tumors (73), also inhibited pp28-GFP
expression with an IC50 of 20 nM with limited toxicity to
uninfected cells (Fig. 4C, 4D, Table I). We confirmed the
specificity of dinaciclib by showing that dinaciclib specifically
prevented the binding of CDKs to MIB beads (supplemental
Fig. S4, supplemental Tables S7 and S8).
MELK is believed to play a critical role in cell cycle regula-
tion, and HCMV specifically modulates the cell cycle to sup-
port replication. OTSSP167 was discovered as a potent MELK
inhibitor and was the first commercially available MELK inhib-
itor. Although the specificity of OTSSP167 is uncertain, it is
currently in phase I/II clinical trials for the treatment of solid
tumors and leukemias, is well tolerated and bioavailable in
vivo (74). OTSSP167 decreased pp28-GFP fluorescence with
an IC50 of 	 5.4 nM which was 18 times lower than the toxic
dose observed for fibroblasts (Fig. 4C, 4D, Table I). These
results suggest that compounds that inhibit MELK, select
CDKs, Chk1, and the BRD family of proteins may have po-
tential as antiviral drugs. In addition, these data demonstrate
the utility of MIB-MS kinome profiling to identify specific ki-
nase inhibitors currently used in humans that could be repur-
posed to treat HCMV disease.
The OTSSP167 is a Potent Inhibitor of HCMV Replication—
Dinaciclib and OTSSP167 exhibited IC50 concentrations sig-
nificantly lower than the IC50 of the current frontline HCMV
antiviral gancyclovir (approx. 1.7 M (75). Based on the low
IC50 value of OTSSP167, we further characterized the effect of
OTSSP167 on the HCMV lytic cycle. We began by confirming
TABLE I
Kinase inhibitors tested for HCMV inhibition. List of kinase inhibitors and their target(s). The stage of clinical testing is listed for those drugs
currently in clinical trials. Inhibition of HCMV replication (IC50 values) was determined using the pp28-GFP assay (N.D.  drug does not reach
50% inhibition at concentrations tested). Cellular toxicity (LD50 values) was determined by LDH assay in uninfected primary human fibroblasts
Drug name Target Clinical stage IC50 LD50
OTSSP167 MELK Phase I/II 5.4 nM 98 nM
Dinaciclib CDK1, 2, 5, 9 Phase 3 20 nM 10 M
OTX015 BRD2,3,4 Phase 1 8.4 M 10 M
LY2603618 Chk1 10 M 10 M
Tivantinib c-Met Phase 3 10 M 10 M
Alisertib AURKA Phase 3 10 M 10 M
Saracatinib c-Src, v-Abl, lyn Phase 1/2 10 M 10 M
BMS-777607 c-Met, Axl, Ron, TYRO3 Phase 1/2 10 M 10 M
Sotrastaurin PKC (pan) Phase 1/2 10 M 10 M
TG003 CLK1,2,4 10 M 10 M
SBI-0206965 ULK1/2 10 M 10 M
PF-03814735 AURKA, AURKB Flt1, FAK, TrkA Phase 1 N.D. 1.7 M
UNC2025 MERTK N.D. 1.2 M
MRT67307 IKK(epsilon), TBK1 N.D. 1.1 M
Repurposing Kinase Inhibitors as Antivirals
Molecular & Cellular Proteomics 16 Supplement 4 S271
the antiviral efficacy of OTSSP167 on the production of infec-
tious wild type HCMV. Infected cells were treated with a range
of OTSSP167 concentrations at the time of infection, and the
abundance of cell-free HCMV in culture supernatants at 96 h
after infection was measured by the TCID50 assay. OTSSP167
inhibited the production of infectious virus in a dose-depend-
ent manner (Fig. 5A), further confirming that decreased pp28-
GFP expression correlates with decreased HCMV replication.
We next measured the effect of OTSSP167 at its IC90 (20 nM,
as determined by the pp28-GFP assay) on virus replication
over a single cycle of virus growth. OTSSP167 was added at
the time of infection, and replenished every 48 h. Importantly
this concentration of drug was not toxic to uninfected cells at
48 h after treatment (data not shown). Infectious cell-free virus
was first detected in untreated cell supernatants at 72 h after
infection, however no virus was observed in OTSSP167-
treated cells at this time point (Fig. 5B). The amount of cell free
virus produced by untreated cells increased at 96 and 120 h
after infection, however virus yield in OTSSP167-treated cells
was reduced by  2 orders of magnitude at these later times.
To better define the step in replication blocked by OTSSP167,
we measured the expression of representative HCMV imme-
diate early (IE1), early (pUL44) and late (pp28) proteins in
OTSSP167-treated infected cells (Fig. 5C). IE1 protein levels
were slightly reduced at 6 h after infection in OTSSP167-
treated cells, but recovered to similar levels observed in un-
treated cells by 24 h after infection and remained constant
thereafter. In contrast, the expression of the early protein
UL44 and late protein pp28 was reduced and delayed in
OTSSP167-treated cells compared with untreated cells. As
expression of pUL44 is required for viral DNA accumulation,
we next examined the levels of viral DNA in OTSSP167-
treated cells (Fig. 5D). We found that viral DNA accumulated
to lower levels in OTSSP167-treated cells compared with
controls. The levels of HCMV proteins correlated with the
abundance of viral transcripts; IE1 mRNA levels were similar
FIG. 5. OTSSP167 inhibits HCMV infection. A, Primary fibroblasts were infected with HCMV and treated with varying concentrations of
OTSSP167 at the time the inoculum was removed. The amount of virus in cell free supernatants was quantified by the TCID50 assay at 96 h
after infection. B, Cells were treated with 20 nM OTSSP167 at the time of infection with HCMV (MOI  1), and cell free virus was quantified as
in A at the indicated times after infection. C, Cells were infected as B, and harvested at the indicated times. Viral protein expression was
measured by Western blot. Tubulin protein expression was used as a loading control. The results are representative of three independent
experiments. D, Cells were infected with HCMV at an MOI of 0.05, and treated either OTSSP167 (20 nM) or PAA (200 g/ml) when the inoculum
was removed. Intracellular viral DNA abundance was measured by qPCR at 96 h after infection. E, Cells were infected as in C. The abundance
of the indicated viral transcripts was measured by qRT-PCR (black boxes  untreated; open boxes  OTSSP167). All experiments were
performed at least three times. The graphs in A, B, D an E show the mean and standard error of three independent experiments.
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in treated and untreated cells, whereas OTSSP167 reduced
the accumulation of UL44 and pp28 (UL99) mRNAs (Fig. 5E).
Together these data confirm that OTSSP167 inhibits the
HCMV lytic cycle at low nanomolar concentrations that are
not toxic to uninfected cells. In addition, these results confirm
the accuracy of the pp28-GFP assay, and demonstrate the
utility of kinome profiling for identifying drugs that may be
repurposed as novel antivirals.
DISCUSSION
In this study we sought to apply MIB-MS kinome profiling to
define changes in the host kinome during HCMV infection.
Our ultimate goal was to use this methodology to identify
kinase inhibitors that could potentially be repurposed as novel
HCMV antivirals. Although other studies have approached the
impact of HCMV infection on the proteome more broadly (76,
77), our studies were specifically focused on characterizing
the kinome. The results of this study identified global changes
in the kinome after infection with either the lab-adapted
AD169 strain or the clinical strain TB40E. Both strains induced
surprisingly similar changes to the kinome, suggesting that
both lab-adapted and clinical strains modify host signaling
pathways in a similar manner.
Changes in cellular kinase activity induced by HCMV infec-
tion have previously been identified on a case-by-case basis
using traditional molecular virology approaches. Although
useful, the vast number of cellular kinases prohibits a com-
prehensive analysis of the kinome in response to infection
using standard techniques. Using MIB-MS kinome profiling,
we were able to measure the effect of infection on 250
cellular kinases in a single sample (28–30). This provided a
global view of kinome reprogramming in HCMV infected cells,
and identified cellular signaling pathways that were signifi-
cantly affected by HCMV infection. Many of the kinome
changes observed matched previous reports, confirming that
MIB-MS profiling accurately identifies changes in kinase ex-
pression/abundance during HCMV infection (9, 21, 78). Im-
portantly, we identified perturbations in several signaling
pathways that have not previously been examined during
infection, highlighting the utility of kinome profiling for identi-
fying novel kinases/signaling pathways that may play critical
roles in HCMV replication.
Our results also confirmed previously reported changes to
cellular signaling pathways during infection (21, 22, 78–82),
and identified several new pathways manipulated by HCMV.
This included multiple receptor kinases, some that were up-
regulated and many that were downregulated after infection.
We validated several of the changes by Western blotting in
particular the decreased expression of the Eph receptor
(EphA2, B4) tyrosine kinases. Membrane bound ephrins bind
their cognate Eph receptors on neighboring cells to induce
bidirectional signaling events that affect cell adhesion and
growth (83). The decreased expression of multiple Eph recep-
tors in infected cells suggests that HCMV might limit ephrin
mediated cell-to-cell communication. Interesting, the study of
Weekes et al. also detected significant down-regulation of
Eph proteins including EphB2 after HCMV infection (77).
Downregulation of this and/or other Eph proteins may be in-
volved in immune evasion as suggested. Conversely, we found
that a specific subset of ephrins continue to be expressed
during infection. Given the variety of functions ephrins play in
cell biology (59), our results warrant additional studies to under-
stand the role of ephrin signaling during HCMV infection.
Similarly, infection decreased the amount of TGF receptor
subunits recovered with MIBs beads. This likely reflects a
decrease in TGF receptor kinase activity, as the expression
of the TGF receptor remains constant during infection, how-
ever infected cells fail to induce SMAD phosphorylation in
response to TGF treatment. The mechanism of TGF recep-
tor inhibition is currently unclear, as is the underlying biolog-
ical significance of its inhibition in primary human fibroblasts.
However, inhibition of TGF signaling might play an important
role in HCMV replication in other cell types. HCMV induces an
M1 macrophage-like phenotype in infected monocytes, which
promotes virus replication (84). Because TGF signaling pro-
motes M2 macrophage differentiation (85), blocking TGF
receptor signaling could drive infected monocytes to differ-
entiate into M1 macrophages, potentially promoting HCMV
replication and spread in infected hosts.
We also identified multiple kinases whose quantification
after MIB-MS was increased after infection. These kinases
may be crucial for increased replication and/or host cell sur-
vival. For example, MELK is believed to be important for
increased cell proliferation and survival in cancer (53). Previ-
ous studies found that MELK regulates cell cycle progression,
and HCMV specifically modifies the cell cycle to support virus
replication. This suggests that MELK activation promotes
HCMV replication and early gene expression by modulating the
cell cycle. The temporal increase in MELK detected by MIB-MS
was confirmed by Western blotting. Moreover, this change was
consistent with the temporal increase and decrease in the
MELK substrate eIF4B (86). Whether MELK phosphorylation of
this protein affects its stability remains to be determined.
We also detected an increase in a number of CDKs, includ-
ing CDK9 after HCMV infection. Consistent with previous
studies that CDK inhibitors inhibit viral early gene expression,
DNA accumulation and late gene expression (81, 82), we
found that dinaciclib, a broad CDK inhibitor, potently inhibits
HCMV replication. These results warrant further investigation
of cell cycle inhibitors as HCMV antivirals.
Using our newly developed assay to quantify virus replica-
tion, we tested inhibitors against the induced kinases as po-
tential antivirals. Although applied on a small scale, the po-
tential for this assay to be used in high-throughput screens is
evident from our studies. Based on our kinome profiling re-
sults, and focusing on drugs in clinical use or development,
we identified three kinase inhibitors that significantly de-
creased HCMV replication. The fact that 3 of only 13 tested
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drugs inhibited HCMV replication (Table I) suggests that a
more extensive analysis would likely identify additional kinase
inhibitors that limit virus replication.
The potential for HCMV-induced kinases to serve as targets
for antiviral drugs was highlighted by our finding that the
reported MELK inhibitor OTSSP167, potently decreased
HCMV replication by limiting early gene transcription and viral
DNA accumulation. Additional studies revealed that OTSSP167
inhibited the production of infectious progeny virus at non-
toxic concentrations in a dose-dependent manner by inhibit-
ing HCMV early protein expression and viral DNA accumula-
tion. Importantly OTSSP167 inhibited HCMV replication at a
nontoxic dose that is clinically achievable in humans. Because
OTSSP167 has already been evaluated for safety and efficacy
in humans, these data suggest a potential novel use as an
HCMV antiviral. Currently the mechanism by which OTSSP167
inhibits early gene transcription is unknown. Although a recent
study questioned the specificity of OTSSP167 and showed
that it could inhibit additional kinases including the Aurora
kinase (87), our experiments with the Aurora inhibitor Alisertib
failed to recapitulate the effects of OTSSP167, suggesting
that inhibition of Aurora alone was insufficient to block viral
replication. Additional studies are necessary to determine if
the antiviral effects of OTSSP167 is through inhibition of
MELK or other kinases. Despite concerns about its specificity,
OTSSP167 demonstrated the greatest potency and lowest
toxicity of the compounds tested herein.
Together these data demonstrate the utility of kinome pro-
filing for identifying changes in cellular kinase activity and/or
expression during HCMV infection. These data also show that
defining HCMV-induced kinome reprogramming is a powerful
approach for identifying drugs in clinical use or development
that may be repurposed as novel HCMV antivirals. Future
studies to identify cell-type specific changes in kinase activity
in response to HCMV infection may reveal additional cellular
kinases that could also be targeted to limit HCMV disease.
Moreover, this approach may be useful for identifying com-
mon changes to cellular signaling pathways in response to
infection with additional viruses, potentially allowing for the
development of broad spectrum antiviral drugs. Ultimately
this approach could save millions of dollars and many years of
testing compared with the traditional antiviral drug develop-
ment process.
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